Company MyMD Pharmaceuticals, Inc.

Equities

MYMD

US62856X2018

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
3.33 ^USD	+2.46%		+17.25%	-57.09%

18/04	MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	CI
09/04	Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	MT

MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Companyâs MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Companyâs second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Number of employees: 6

Managers	Title	Age	Since
Christopher Chapman PSD	President	71	01/20/01
Ian Rhodes DFI	Director of Finance/CFO	51	15/21/15
Christopher Schreiber BRD	Director/Board Member	58	08/17/08
Robert Schatz IRC	Investor Relations Contact	-	-
Jenna Brager LAW	General Counsel	-	01/21/01

Members of the board	Title	Age	Since
Christopher Schreiber BRD	Director/Board Member	58	08/17/08
Christopher Chapman PSD	President	71	01/20/01
Joshua Silverman CHM	Chairman	53	06/18/06
Bill White BRD	Director/Board Member	63	08/17/08
Craig Eagle BRD	Director/Board Member	57	16/21/16
Jude Uzonwanne BRD	Director/Board Member	50	16/21/16

	Vote	Quantity	Free-Float	Total Float
Stock A	0	9,859	0	92.68 %
Stock B	0	72,992	0
Stock C	1	2,157,632	1,999,627 ( 92.68 %)

Name	Equities	%	Valuation
Global X Management Co. LLC 40.60 %	875,933	40.60 %	2 M $
Caroline C Williams 5.785 %	124,815	5.785 %	298 308 $
Vanguard Global Advisers LLC 2.253 %	48,609	2.253 %	116 176 $
Richard Abbe 1.427 %	30,791	1.427 %	73 590 $
Paul Rivard 0.6180 %	13,334	0.6180 %	31 868 $
Geode Capital Management LLC 0.4499 %	9,708	0.4499 %	23 202 $
BlackRock Institutional Trust Co. NA 0.3069 %	6,622	0.3069 %	15 827 $
Iroquois Capital Management LLC 0.2895 %	6,247	0.2895 %	14 930 $
Cambria Investment Management LP 0.2651 %	5,719	0.2651 %	13 668 $
Joshua Silverman 0.2317 %	5,000	0.2317 %	11 950 $

Name	Equities	%	Valuation
Iroquois Capital Management LLC 13.89 %	2,083	13.89 %	4 978 $

Name	Equities	%	Valuation
Premas Biotech Pvt Ltd. 34.54 %	72,992	34.54 %	174 451 $

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street Suite 601

21205, Baltimore

http://www.mymd.com

address MyMD Pharmaceuticals, Inc.(MYMD)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MYMD PHARMACEUTICALS, INC.	-57.09%	7.01M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs